EBV

Scientists have created an assay that can measure immune cells’ inflammatory attack against the Epstein-Barr virus (EBV), a known risk factor for multiple sclerosis (MS). Researchers found preliminary evidence that some MS treatments, but not others, may alter the immune system’s response to EBV. The scientists said the…

People with multiple sclerosis (MS) have high levels of T-cells in their spinal fluid that specifically target cells infected with the Epstein-Barr virus (EBV), according to a new study. These T-cells were found in samples collected from patients during their diagnostic workup in the early stages of…

A history of infection with Epstein-Barr virus (EBV) has been shown to be a strong risk factor for developing multiple sclerosis (MS) — but is targeting the virus a viable strategy for MS prevention or treatment? This question was the subject of a debate, “How To…

Scientists have identified a number of antibodies that can bind to the Epstein-Barr virus (EBV) — a major risk factor for multiple sclerosis (MS) — and prevent its infection of human cells. The antibodies might offer new approaches to treat or prevent infection in groups of people most…

A National Multiple Sclerosis Society grant is supporting an Australian-led research team aiming to better understand how the Epstein-Barr virus (EBV) may be acting as a trigger for multiple sclerosis (MS). The funding will particularly be used to understand what molecules are being targeted by lymphocytes, immune cells that…

People who had infectious mononucleosis — a contagious disease for which the Epstein-Barr virus (EBV) is the leading cause — had a higher incidence of multiple sclerosis (MS) in the 10 years following diagnosis compared with individuals not diagnosed with the virus, a study found. This link was particularly…

An independent committee of experts has recommended that the Phase 2 portion of the EMBOLD clinical trial continue as planned without a sample size adjustment, following an analysis of safety and effectiveness data. The trial is testing Atara Biotherapeutics‘ experimental medication ATA188 in progressive forms of multiple…

Atara Biotherapeutics plans to launch two Phase 3 clinical trials of its investigational immunotherapy ATA188 in people with non-active, progressive forms of multiple sclerosis (MS). Whether efforts for these trials will go forward, however, depends on positive results from an interim analysis of the Phase 2 portion of the…

The Australian government has announced that a record AU$18 million (about $13.5 million) from the Medical Research Future Fund will be used to support research into multiple sclerosis (MS) as part of its 2022–23 budget. Grant opportunities will focus on increasing access to clinical trials and speeding the development of effective…

Tevogen Bio is planning to make use of its virus-fighting immune cell technology and turn it against Epstein-Barr virus (EBV), a common virus thought to greatly increase the risk of multiple sclerosis (MS). The technology employs off-the-shelf cytotoxic T-cells — a type of white blood cell that can…

Infection with the common Epstein-Barr virus (EBV) increases the risk of developing multiple sclerosis (MS) by 32 times — the strongest link yet — according to a study looking at two decades of data from more than 10 million U.S. military members. “The hypothesis that EBV causes MS has been…

An investigational immunotherapy, ATA188 showed it could reverse disability and improve exercise capacity in people with progressive forms of multiple sclerosis (MS), Atara Biotherapeutics, its developer, reported in an update on a Phase 1 trial and its long-term extension study. EMBOLD trial findings based on MRI brain imaging…

Experiencing serious infections during adolescence is tied to an increased risk of developing multiple sclerosis (MS) later in life, but those occurring in childhood don’t increase MS risk, according to a new Swedish study. The study also found that certain types of infections, especially those that affect the central…

An antibody analysis has identified two biomarkers that can be used to predict the development of multiple sclerosis (MS) in people with optic neuritis, a study reports.  Further research is, however, required to validate these findings…

ATA188, Atara Biotherapeutics’ investigative T-cell immunotherapy, is safe, well tolerated, and able to ease disability and improve exercise capacity in patients with progressive forms of multiple sclerosis (MS), according to one-year data from a Phase 1 trial and its long-term extension study. Findings also showed that, after…

Genetic variants may contribute to increased levels of antibodies against proteins of the Epstein-Barr virus — a known environmental risk factor for multiple sclerosis (MS) — in MS patients and their siblings, a study suggests. The study, “EBNA-1 titer gradient in families with multiple sclerosis indicates a…

Cigarette smoking and an Epstein–Barr virus infection together represent a significant risk factor for multiple sclerosis (MS), suggesting that at least one path to this disease involves two factors working synergistically, a study reports. The study, “Smoking and Epstein–Barr virus infection in multiple sclerosis development,” was published…

Immune B-cells that proliferate unchecked when infected by the Epstein-Barr virus (EBV) appear to increase the risk of relapses in patients with multiple sclerosis (MS), a mouse study suggests. The study, “Epstein Barr virus‐immortalized B lymphocytes exacerbate experimental autoimmune encephalomyelitis in xenograft mice,” was published…

Atara Biotherapeutics has enrolled a first patient in a clinical trial testing ATA188, its off-the-shelf T-cell immunotherapy for people with progressive forms of multiple sclerosis (MS). The Phase 1b trial (NCT03283826) follows promising safety and tolerability results from its open-label Phase 1a part, including a…

Atara Biotherapeutics‘ cell-based therapy ATA188 is safe and well-tolerated in people with progressive forms of multiple sclerosis (MS), and induces a sustained reduction in disability in a dose-dependent manner, findings from the first part of a Phase 1 clinical trial show. ATA188 had an…

Supporting evidence that infection with Epstein-Barr virus (EBV) could be one of the root causes of multiple sclerosis (MS), a recent study found all of its 901 early disease patients carry antibodies against this virus, meaning that all are or have been exposed to it. The study, “…

In response to the COVID-19 pandemic, Atara Biotherapeutics has temporarily paused patient enrollment in the second and randomized part of its ongoing Phase 1 clinical trial investigating ATA188 in people with progressive forms of multiple sclerosis (MS). People treated in the first, open-label part of this trial, however,…

Interaction between various Epstein-Barr virus traits and the composition of certain genes affects the risk of developing multiple sclerosis (MS), a study reports. The study, “The interaction of Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis,” was published in the journal…

People with progressive forms of multiple sclerosis (MS) and past exposure to the Epstein-Barr virus are responding to a potential immunotherapy known as ATA188, tolerating the treatment well and with signs that suggest effectiveness, early updated data from an ongoing Phase 1 trial show. The research, “…

Infection with the human herpesvirus (HHV)-6A may increase the likelihood of having multiple sclerosis (MS), according to a new national study in Sweden. The research, “Serological response against HHV-6A is associated with increased risk for multiple sclerosis,” was presented by Anna Fogdell-Hahn, PhD, associate professor at the…

Multiple sclerosis (MS) experts discuss disease causes and current treatment options in a new video series released by the multimedia and peer-reviewed science journal, The American Journal of Managed Care (AJMC).  The free and online video series is part…

Early, positive safety results from a Phase 1 trial testing a potential immunotherapy, ATA188, in people with progressive multiple sclerosis will be detailed at the 5th Congress of the European Academy of Neurology (EAN) late next month, its developer, Atara Biotherapeutics, announced. ATA188 is an investigational and “off-the-shelf”…

Multiple Sclerosis News Today brought you daily coverage of key findings, treatment developments, and clinical trials related to multiple sclerosis (MS) throughout 2018. We look forward to reporting more news to patients, family members, and caregivers dealing with MS during 2019. Here are the top 10 most-read articles of…

Atara Biotherapeutics’ investigational ATA190, a cell therapy that wipes out immune B-cells infected with the Epstein-Barr virus (EBV), led to neurological improvements and reduced symptoms in patients with primary and secondary progressive multiple sclerosis (MS), a Phase 1 trial shows. The trial results were published in the Journal…

Analysis of post-mortem brain samples from multiple sclerosis (MS) patients and healthy individuals (without neurologic disease) showed that while signs of Epstein-Barr virus (EBV) infection are present in both groups of brains, EBV-positive immune cells were more prevalent and densely populated in the MS brain. The study reporting those findings,…